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Background. Leprosy morbidity is increased by 2 pathologic immune reactions, reversal reaction (RR) and er-
ythema nodosum leprosum (ENL).
Methods. To discover host factors related to immune reactions, global transcriptional proﬁles of peripheral
blood mononuclear cells were compared between 11 RR, 11 ENL, and 19 matched control patients, with conﬁrma-
tion by quantitative polymerase chain reaction. Encoded proteins were investigated in skin biopsy specimens by
means of immunohistochemistry.
Results. There were 275 genes differentially expressed in RR and 517 differentially expressed in ENL on the mi-
croarray. Pathway analysis showed immunity-related pathways represented in RR and ENL transcriptional proﬁles,
with the “complement and coagulation” pathway common to both. Interferon γ was identiﬁed as a signiﬁcant up-
stream regulator of the expression changes for RR and ENL. Immunohistochemical staining of skin lesions showed
increased C1q in both RR and ENL.
Conclusions. These data suggest a previously underrecognized role for complement in the pathogenesis of both
RR and ENL, and we propose new hypotheses for reaction pathogenesis.
Keywords. leprosy; reversal reaction; erythema nodosum leprosum; complement.
Leprosy, or Hansen’s disease, remains a signiﬁcant chal-
lenge to global health despite the availability of antibi-
otic therapy. A total of 232 857 cases were reported in
2012, including 33 303 new cases in Brazil [1]. Infection
with Mycobacterium leprae, the causative agent of lep-
rosy, manifests as a spectrum of clinical presentations.
These range from the tuberculoid form, with few skin
lesions and strong cell-mediated immune response, to
the lepromatous form (LL), with disseminated disease
and predominant humoral response [2]. Individuals
with intermediate immune response to M. leprae devel-
op “borderline” clinical forms: borderline tuberculoid
(BT), borderline-borderline, and borderline leproma-
tous (BL) [2]. About 30% of persons with leprosy will
develop a pathologic immune reaction of leprosy, either
reversal reaction (RR) or erythema nodosum leprosum
(ENL) [3]. These reactions are common during the ﬁrst
3 months of antileprosy therapy but can occur before,
during, or after treatment of leprosy.
The ﬁrst common reaction, RR, results in swelling
and inﬂammation of existing skin lesions with increas-
ing neuritis and nerve damage. It is thought to be relat-
ed to an augmented cell-mediated immune response to
M. leprae antigens in the skin and nerves in persons
with borderline forms of leprosy [4, 5]. Clinical risk fac-
tors for RR include increased age, >5 skin lesions, and
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high M. leprae bacterial load [6]. A pronounced T-helper (Th)
1–type response to M. leprae antigens has been documented in
the skin of patients with RR [7]. Persons with history of RR can
maintain an altered response to M. leprae antigen that differs
from patients with nonreaction leprosy for years after resolution
of RR [8].The other common reaction, ENL, occurs in leproma-
tous (BL or LL) leprosy with painful subcutaneous nodules and
systemic ﬁndings, such as fever, arthritis, nephritis, and panni-
culitis [9]. Its pathogenesis seems to be related to formation and
deposition of immune complexes in skin and organs [9]. Risk
factors for ENL include LL clinical form and high bacterial
load [10].
The immune reactions of leprosy are typically chronic and re-
current and can require years of treatment with corticosteroids
or other immunomodulatory medications [10]. Neurologic se-
quelae from leprosy reactions can be irreversible even with ap-
propriate therapy, signiﬁcantly increasing the morbidity and
disability due to leprosy [11]. Potential biomarkers have been
proposed for RR and ENL but have not been validated for
predicting reactions [12,13].Transcriptional proﬁling of skin le-
sions has shown differences between tuberculoid and leproma-
tous skin lesions [14], although these were not studied in
relation to systemic immune proﬁles in blood leukocytes. In-
creased interferon (IFN) α pathway transcripts in RR lesions
suggest its involvement in pathogenesis [15], and a recent
study showed that persons with history of RR had a unique
gene expression proﬁle in response to M. leprae antigen in
vitro [8]. Studies of the transcriptional proﬁles of immune
cells from subjects with active RR and ENL are needed to un-
derstand the systemic immune response during reactions. We
hypothesized that RR and ENL are caused by distinctly different
immune responses. To test this hypothesis, we generated tran-
scriptional proﬁles of peripheral blood mononuclear cells
(PBMCs) of carefully characterized subjects with symptomatic
leprosy immune reactions and matched controls with validation
studies including quantitative polymerase chain reaction
(qPCR), ﬂow cytometry, and immunohistochemistry.
MATERIALS AND METHODS
Human Subjects
Adult patients with leprosy were enrolled from Hansen’s disease
treatment centers in Rio Grande do Norte, Brazil. Leprosy
clinical forms were assigned by a trained dermatologist
(M. d. C. A. P. Q., L. L. M., or M. L. N.) based on Ridley-Jopling
criteria [2].Diagnoses of RR or ENL were based on clinical ﬁnd-
ings [16, 17]. Excluded from this study were persons with
known immunodeﬁciency or who had received corticosteroids
within 7 days or thalidomide within 28 days of enrollment.
Transcript microarrays were obtained from 22 patients with
leprosy with immune reaction (11 RR and 11 ENL) and 19 con-
trols without reactions matched to cases for age, sex, leprosy
clinical form, and stage of treatment. PBMCs for reverse-
transcription qPCR validation were derived from a subset of
these participants and an additional 28 persons (11 RR, 6
ENL, and 11 controls). Monocyte populations were compared
in the different leprosy clinical groups using ﬂow cytometry
of PBMCs. Skin biopsy immunohistochemical studies were
completed for 16 patients with leprosy (3 RR, 3 ENL, 7 BT con-
trols, and 3 BL/LL controls).
PBMC Isolation and RNA Extraction
PBMCs were isolated from heparinized peripheral blood using a
Ficoll-Paque PLUS gradient (GE Healthcare Life Sciences).
RNA was isolated using Trizol (Life Technologies) and puriﬁed
with a RNeasy MinElute Cleanup Kit (Qiagen) with on-column
DNase treatment.
Microarray and Analysis
Preparation of RNA for hybridization to Illumina BeadChips
(Ambion) was performed at the University of Iowa DNA
Core Facility using the manufacturer’s protocol. After hybridi-
zation, the arrays were washed, blocked, and stained according
to the Illumina Whole-Genome Gene Expression Direct Hy-
bridization Assay protocol. BeadChips were scanned with the
Illumina iScan System and data collected using GenomeStudio
software (Illumina, version 2011). Data sets were compared
using Rank Products Analysis (Bioconductor utilities; www.
bioconductor.org, last accessed December 1, 2014) to optimize
comparison of array groups of small sample size and with var-
iability inherent in human clinical samples [18, 19]. Quantile
normalized ﬂuorescence results were analyzed with the Rank-
Prod library using RPadvance software in R package (v2.36.0,
http://www.r-project.org, last accessed December 1, 2014), con-
sidering arrays run on separate days as different origins. The re-
sultant orders were compared with topGene software, with a
percentage false-positive (FPR) cutoff of 0.05. Reported fold
changes for the array are given as log2 fold change.
Transcripts with a FPR cutoff ≤0.05 and fold change ≥1.5
were used for pathway analyses. Kyoto Encyclopedia of Genes
and Genomes (KEGG) and Gene Ontology (GO) Biological
Process pathways were generated with Webgestalt (2014,
Vanderbilt University) [20] with Bonferroni correction. Inge-
nuity Pathway Analysis (IPA) (Qiagen) was completed using
experimentally observed direct and indirect relationships for
humans.
qPCR With Taqman Low Density Arrays
Signiﬁcantly changed microarray transcripts were selected for
validation with Taqman Low Density Arrays. PBMC-derived
complementary DNA was applied in duplicate to custom Taq-
man Low Density Arrays (Life Technologies). Fluorescence was
normalized to the array baseline in Expression Suite software
(version 1.0; Life Technologies) and mean cycle threshold
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(Ct) values were compared using 2-tailed t tests. Delta-delta
cycle threshold (ΔΔCt) values were converted to fold changes
using this calculation: fold change = 2(−ΔΔCt).
Immunohistochemistry of Skin Biopsy Specimens
Skin biopsy specimens were collected in formalin and ﬁxed in
parafﬁn. After sectioning, slides were deparafﬁnized and sub-
jected to antigen retrieval. Sections were stained with rabbit
anti-human C1q (clone 9A7; Abcam) and mouse anti-human
CD21 (clone EP3093; Abcam) with secondary staining with
goat anti-rabbit AlexaFluor488 and goat anti-mouse-Alexa-
Fluor546 (Life Technologies). Stained tissue sections were im-
aged using a Zeiss Examiner.Z1 AX10 confocal (LSN 7100)
microscope and recorded using Zen 2010BSP1 software
(Zeiss). Intensity, laser range, and gain were constant. For
each biopsy specimen, 2 adjacent 15-section micrographs
were obtained 1 mm from the edge of the specimen at the der-
mal-epidermal border with an additional 2 dermal photographs
just internal to the initial photographs. Mean intensities of
ﬂuorescence were normalized to the BT group for each day of
staining and compared using analysis of variance with Tukey
posttest. Imaging and analysis were completed by authors
(F. M. A. and M. R. C.) blinded to the group assignment.
Flow Cytometry
A total of 250 000 PBMCs were stained with anti–CD14-
allophycocyanin–cyanine 7 (Ebioscience), and 50 000 events
were counted using a FACS-Canto II ﬂow cytometer (Becton
Dickinson) and recorded with FACSDiva software (Becton
Dickinson). Data were analyzed using FlowJo software
(v 9.5.3, TreeStar) with monocyte gate and CD14 positivity as-
signed as in Supplementary Figure 1A. Monocyte populations
were compared using analysis of variance with Tukey multiple-
comparison tests for normally distributed data, and Kruskal–
Wallis test with Dunn multiple comparison for non-normally
distributed data.
Ethical Considerations
The study was reviewed and approved by the institutional review
boards of the Universidade Federal do Rio Grande do Norte, Bra-
zil’s National Ethical Review Board, and Weill Cornell Medical
College. The Brazilian institutional review board is registered
with the USNational Institutes of Health. All participants provid-
ed written informed consent for participation in the study.
RESULTS
Study Population
The study population for the transcript microarray included 22
patients with leprosy with immune reaction (11 RR and 11
ENL) matched 1:1 for age, sex, leprosy clinical form, and
stage of treatment with a control patient without reaction
(Table 1). PBMCs used for qPCR were from a subset of these
subjects and another 28 patients with leprosy. Additional sam-
ples included in the RR qPCR validation were RR (n = 11) and
non-RR controls (n = 7). Age (mean, 50 vs 51 years; P = .89), sex
(59.1% vs 55.6% male; P = .82), and clinical form of leprosy
(P = .96) did not differ signiﬁcantly between RR and non-RR
groups. Additional samples included in the ENL qPCR valida-
tion were ENL (n = 6) and non-ENL controls (n = 4). Age (45 vs
51 years; P = .33), sex (82.4% vs 60% male; P = .24), and clinical
Table 2. Top 10 GO Biological Process Pathways Among the Set
of Differentially Expressed Genes in RR
GO Pathway
Genes in
Pathway,
No.
Genes
Changed
in RR, No. R
Adjusted
P Value
Immune response 1071 52 3.92 3.96 × 10−15
Defense response 1107 52 3.80 1.64 × 10−14
Immune system
process
1792 66 2.98 4.78 × 10−14
Response to stress 2952 82 2.25 2.32 × 10−11
Innate immune
response
539 30 4.50 5.93 × 10−9
Response to stimulus 6636 125 1.52 1.21 × 10−7
Response towounding 1109 40 2.92 8.09 × 10−7
Humoral immune
response
124 13 8.47 6.51 × 10−6
Response to external
stimulus
1323 42 2.57 1.26 × 10−5
Fibrinolysis 24 7 23.58 1.73 × 10−5
Abbreviations: GO, Gene Ontology; RR, reversal reaction.
Table 1. Baseline Characteristics of the Patients With Leprosy
Included in the Microarray Analysis
Characteristic
RR
(n = 11)
Controls
Without RR
(n = 11)
ENL
(n = 11)
Controls
Without ENL
(n = 11)
Male sex, % 54.5 54.5 81.8 81.8
Age, mean
(range), y
47.6
(22–73)
46.8
(28–65)
43.9
(23–65)
48.3
(27–69)
Leprosy treatment status, No.
Pretreatment 5 6 3 5
On treatment 5 5 2 6
Posttreatment 1 0 6 0
Ridley-Jopling clinical form of leprosy
BT 3 2 0 0
BB 3 4 0 0
BL 5 5 6 6
LL 0 0 5 5
Abbreviations: BB, borderline-borderline; BL, borderline lepromatous; BT,
borderline tuberculoid; ENL, erythema nodosum leprosum; LL, lepromatous
leprosy; RR, reversal reaction.
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form of leprosy (P = .47) did not differ signiﬁcantly different be-
tween ENL and non-ENL groups.
Pathway Analysis of Transcriptomes
The ﬁrst aim of this study was to characterize the transcriptome
proﬁles associated with the transition of leprosy to either RR or
ENL. Comparing RR with non-RR controls, there were 275 dif-
ferentially expressed genes (n = 203 increased and n = 72 de-
creased in RR). Comparing ENL with non-ENL controls,
there were 517 differentially expressed genes (n = 300 increased
and n = 217 decreased in ENL). Differentially expressed genes
are listed in Supplementary Table 1.
Considering all differentially expressed genes in RR, the top
GO Biological Process pathways were related to the immune re-
sponse: immune response, defense response, immune system
process, response to stress, and innate immune response
(Table 2). Consistently, the top 3 KEGG pathways were
Table 3. Signiﬁcant KEGG Pathways With Pathway Transcripts
Differentially Transcribed in RR
KEGG Pathway (Adjusted
P Value) Transcriptsa (Fold Change; P Value)
Staphylococcus aureus
infection (2.56 × 10−13)
HLA-DRB1 (−1.59; <.0001), C1QB
(2.21; <.0001), C1QA (1.64;
.0004), HLA-DQA1 (1.61; .0001),
FCGR1A (2.78; <.0001), FPR1
(1.80; .0001), C1QC (1.77;
<.0001), C2 (2.31; <.0001),
FCGR3B (2.12; <.0001), HLA-
DOB (−1.50; .0001), FPR2 (2.28;
<.0001)
Complement and coagulation
cascades (4.85 × 10−9)
C1QB (2.21; <.0001), SERPING1
(2.17; <.0001), C1QA (1.64;
.0004), PLAU (2.52; <.0001),
PLAUR (1.84; .0002), C1QC (1.77;
<.0001), PROS1 (1.50; .0003),
C2 (2.31; <.0001), THBD (1.78;
.0001)
Systemic lupus
erythematosus
(7.32 × 10−9)
HLA-DRB1 (−1.59; <.0001), C1QB
(2.21; <.0001), C1QA (1.64;
.0004), HIST2H2AA4 (1.72;
<.0001), HLA-DQA1 (1.61;
.0001), FCGR1A (2.78; <.0001),
C1QC (1.77; <.0001),
HIST2H2AA3 (1.77; <.0001),
C2 (2.31; <.0001), FCGR3B (2.12;
<.0001), HLA-DOB (−1.50; .0001)
Hematopoietic cell lineage
(4.50 × 10−8)
HLA-DRB1 (−1.59; <.0001), FCER2
(−1.5; <.0001), FCGR1A (2.78;
<.0001), CD19 (−1.76; <.0001),
ITGB3 (1.63; .0001), ILI1R2 (2.12;
<.0001), MME (1.59; .0003),
ITGA2B (2.04; <.0001), ANPEP
(1.82; <.0001)
Cytokine-cytokine receptor
interaction (7.38 × 10−8)
CCL7 (3.03; <.0001), PF4V1 (1.81;
<.0001), CXCR5 (−1.65; <.0001),
CXCL10 (2.02; <.0001), CCR7
(−1.73; <.0001), CCL2 (2.90;
<.0001), ILIR2 (2.12; <.0001),
CXCL1 (1.64; .0001), TNFRSF12A
(1.94; <.0001), CCL3 (1.67;
.0002), CD27 (−1.60; <.0001),
CXCR1 (1.61; <.0001), CCL3L1
(1.61; .0001)
Phagosome (4.13 × 10−7) MARCO (1.77; <.0001), CTSL1
(2.11; <.0001), HLA-DRB1
(−1.59; <.0001), CLEC7A (1.71;
.0002), TUBB2A (1.52; .0002),
HLA-DQA1 (1.61; .0001),
FCGR1A (2.78; <.0001), ITGB3
(1.63; .0001), FCGR3B (2.12;
<.0001), HLA-DOB (−1.50; .0001)
Rheumatoid arthritis
(1.35 × 10−6)
CTSL1 (2.11; <.0001), HLA-DRB1
(−1.59; <.0001), HLA-DQA1
(1.61; .0001), CCL2 (2.90;
<.0001), CXCL1 (1.64; .0001),
CCL3 (1.67; .0002), CCL3L1
(1.61; .0001), HLA-DOB (−1.5;
.0001)
Chemokine signaling pathway
(3.09 × 10−6)
CCL7 (3.03; <.0001), PF4V1 (1.81;
<.0001), CXCR5 (−1.65; <.0001),
CXCL10 (2.02; <.0001), CCR7
(−1.73; <.0001), CCL2 (2.90;
<.0001), CXCL1 (1.64; .0001),
CCL3 (1.67; .0002), CXCR1 (1.61;
<.0001), CCL3L1 (1.61; .0001)
Table 3 continued.
KEGG Pathway (Adjusted
P Value) Transcriptsa (Fold Change; P Value)
Chagas disease (.001) C1QB (2.21; <.0001), CCL3 (1.67;
.0002), C1QA (1.64; .0004), CCL2
(2.90; <.0001), CCL3L1 (1.61;
.0001), C1QC (1.77; <.0001)
Leishmaniasis (.002) HLA-DRB1 (−1.59; <.0001), HLA-
DQA1 (1.61; .0001), FCGR3B
(2.12; <.0001), FCGR1A (2.78;
<.0001), HLA-DOB (−1.5; .0003)
ECM receptor interaction
(.004)
SV2A (1.68; .0001), LAMA5 (−1.57;
.0001), ITGA2B (2.04; <.0001),
SDC4 (1.58; .0002), ITGB3 (1.63;
.0001)
Osteoclast differentiation (.03) FOSL1 (1.79; <.0001), FCGR3B
(2.12; <.0001), FCGR1A (2.78;
<.0001), FOSB (1.68; .0001),
ITGB3 (1.63; .0001)
Asthma (.03) HLA-DRB1 (−1.59; <.0001), HLA-
DQA1 (1.61; .0001), HLA-DOB
(−1.5; .0001)
Toxoplasmosis (.04) HLA-DRB1 (−1.59; <.0001),
BCL2L1 (1.61; <.0001), HLA-
DQA1 (1.61; .0001), HLA-DOB
(−1.5; .0001), LAMA5 (−1.57;
.0001)
Cell adhesion molecules (.04) HLA-DRB1 (−1.59; <.0001),
CNTNAP2 (−2.03; <.0001), HLA-
DQA1 (1.61; .0001), HLA-DOB
(−1.5; .0001), SDC4 (1.58; .0002)
Antigen processing and
presentation (.04)
CTSL1 (2.11; <.0001), HLA-DRB1
(−1.59; <.0001), HLA-DQA1
(1.61; .0001), HLA-DOB (−1.5;
.0001)
Prion diseases (.04) C1QB (2.21; <.0001), C1QA (1.64;
.0004), C1QC (1.77; <.0001)
Abbreviations: ECM, extracellular matrix; KEGG, Kyoto Encyclopedia of Genes
and Genomes; RR, reversal reaction.
a Downregulated transcripts with negative fold-changes are in italics.
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Staphylococcus aureus infection (adjusted P = 2.56 × 10−13),
complement and coagulation cascades (adjusted P = 4.85 ×
10−9), and systemic lupus erythematosus (adjusted P = 7.32 ×
10−9) (Table 3). HLA genes (HLA-DRB1 and HLA-DOB),
C1Q, C1 esterase inhibitor (SERPING1), FPR 1, Fc fragment
of IgG receptor (FcγR), and histone (HIST2H2AA3 and
HIST2H2AA4) transcripts were represented in both sets of
pathways. The top canonical pathways for RR identiﬁed by
IPA were granulocyte adhesion and diapedesis (P = 8 × 10−9),
agranulocyte adhesion and diapedesis (P = 1.35 × 10−7), and
B-cell development (P = 6.96 × 10−7). IPA identiﬁed IFN-γ as
the most signiﬁcant upstream regulator of the expression
changes seen in the array (P = 1.44 × 10−13), followed by immu-
noglobulin (1.22 × 10−12). The top associated IPA-identiﬁed
Figure 1. Networks generated by Ingenuity Pathway Analysis for reversal reaction (RR) (A) and erythema nodosum leprosum (ENL) (B). Red indicates
genes upregulated in reaction; green, genes downregulated in reaction; darker shades, greater magnitude of fold change; broken lines, for indirect inter-
actions; solid lines, direct interactions; arrows, activation; bars, inhibition.
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network for RR is shown in Figure 1A and includes pathogen
receptors, chemokines and chemokine receptors, and molecules
that interact with immunoglobulin.
Similar to RR, the top GO Biological Process pathways
changed in ENL were related to the immune response: defense
response, immune system process, response to bacterium, re-
sponse to wounding, and immune response (Table 4). The
top 3 KEGG pathways were S. aureus infection (adjusted P =
1.9 × 10−16), systemic lupus erythematosus (adjusted P = 7.37 ×
10−14), and cytokine-cytokine receptor interaction (adjusted
P = 8.48 × 10−10) (Table 5). The complement and coagulation
pathway (adjusted P = 3.78 × 10−9) was also associated with
ENL. These pathways include components of the classic com-
plement pathway, histones, cytokine receptors, and inﬂamma-
tory response regulators. The top canonical pathways for ENL
identiﬁed by IPA were granulocyte adhesion and diapedesis
(P = 1.46 × 10−12), agranulocyte adhesion and diapedesis
(P = 3.64 × 10−11), and interleukin 8 signaling (P = 2.68 ×
10−6). IPA identiﬁed CCL5 as the most signiﬁcant upstream
regulator of the expression changes in the array (P = 9.78 ×
10−16), followed by IFN-γ (P = 8.88 × 10−15). The top associated
IPA-generated network for ENL is shown in Figure 1B and in-
cludes immunoglobulin receptors, pathogen recognition recep-
tors, and chemokines.
Comparison of RR and ENL Transcriptomes
Another aim of this study was to describe the similarities and
differences in gene expression in RR and ENL (compared
with their respective controls). Considering all differentially ex-
pressed genes, there were 379 transcripts unique to ENL, 137
Figure 1 continued.
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unique to RR, and 138 that had differential expression in both
RR and ENL groups (Tables 6–8). Of those genes with increased
expression, 104 were unique to RR, 201 unique to ENL, and 99
with increased expression in both RR and ENL groups. Among
genes with decreased expression during an immune reaction, 57
were unique to RR, 202 unique to ENL, and 15 with decreased
expression in both groups.
A transcript uniquely increased in RR was CXCL10, which
has previously been studied in association with RR [12]. Also
increased in RR was transglutaminase 2 (TGM2), which is in-
creased in autoimmune disease and may be related to antigen
modiﬁcation [21]. In the RR group, there were increased tran-
script levels of pattern recognition receptor C-type lectin do-
main family 7, member A (CLEC7A [dectin-1]), and a
scavenger receptor, the macrophage receptor with collagenous
structure (MARCO) [22]. There were decreased transcripts of
B-cell-associated molecules CD79, CD19, and CD27 and
T-cell signaling modulator CCR7. IPA biomarkers analysis
identiﬁed chemokine (C-X-C motif ) ligand 10 (CXCL10) and
Fc fragment of IgE, low afﬁnity II (FCER2) as transcripts with
differential levels unique to RR.
Transcripts uniquely increased in ENL included the comple-
ment receptors C3AR1 and C5AR1 and 3 ribonucleases;
RNASE1, RNASE2, and RNASE3. Uniquely decreased tran-
scripts in ENL included interleukin 10 and cytotoxic t-
lymphocyte associated protein 4 (CTLA4), modulators of
T-cell responses. Decreased CTLA4 and interleukin 10 in
ENL could either contribute to the inﬂammatory cascade ob-
served clinically during ENL or reﬂect a relatively high level
of the inhibitory protein in PBMCs of patients with leproma-
tous leprosy without ENL. IPA biomarkers analysis identiﬁed
20 genes as uniquely differentially expressed in ENL compared
with RR including the chemokine ligands CCL3L3 and CXCL8.
Table 4. Top 10 GO Biological Process Pathways Among the Set
of Differentially Expressed Genes in ENL
GO Pathway
Genes in
Pathway,
No.
Genes
Changed
in ENL,
No. R
Adjusted
P Value
Defense response 1107 83 3.39 1.55 × 10−20
Immune system process 1792 101 2.54 1.55 × 10−16
Response to bacterium 349 42 5.43 4.23 × 10−16
Response to wounding 1109 75 3.05 1.67 × 10−15
Immune response 1071 73 3.08 3.54 × 10−15
Response to stress 2952 133 2.03 7.38 × 10−15
Inflammatory response 484 45 4.20 4.86 × 10−13
Response to biotic
stimulus
613 50 3.68 1.89 × 10−12
Response to other
organism
583 48 3.72 5.33 × 10−12
Abbreviations: ENL, erythema nodosum leprosum; GO, Gene Ontology.
Table 5. Signiﬁcant KEGG Pathways With Pathway Transcripts
Differentially Transcribed in ENL
KEGG Pathway (Adjusted
P Value) Transcriptsa
Staphylococcus aureus
infection (1.90 × 10−16)
C1QB (3.27; <.0001), PTAFR (1.89;
.0001), C1QA (1.82; <.0001), HLA-
DQA1 (1.50; .0003), FCGR1A
(2.55; <.0001), SELP (1.62;
<.0001), FPR1 (2.10 P< .0001),
C1QC (2.61; <.0001), C5AR1
(1.83; <.0001), IL10 (−1.57;
.0001), FCGR3B (1.61; .0002),
HLA-DRB5 (−2.22; <.0001), FPR2
(2.15; <.0001), C3AR1 (1.66;
<.0001), FCAR (1.68; .0003)
Systemic lupus
erythematosus
(7.37 × 10−14)
HIST1H3F (1.52; .0001), HIST2H3C
(1.54; .0002), HIST2H2AA4 (2.09;
<.0001), HLA-DQA1 (1.50; .0003),
H2AFJ (1.65; <.0001),
HIST2H2BE (1.77; <.0001),
ELANE (1.92; <.0001), IL10
(−1.57; .0001), HIST1H3H (1.59;
.0001), FCGR3B (1.61; .0002),
HIST2H2AB (1.70; <.0001), C1QB
(3.27; <.0001), C1QA (1.82;
<.0001), FCGR1A (2.55; <.0001),
C1QC (2.61; <.0001),
HIST2H2AA3 (1.98; <.0001),
HIST2H2AC (2.00; <.0001), HLA-
DRB5 (−2.22; <.0001)
Cytokine-cytokine receptor
interaction (8.48 × 10−10)
CCL7 (3.40; <.0001), IL11RA (−1.6;
<.0001), CCL2 (2.70; <.0001),
CXCL2 (2.81; <.0001), IL10
(−1.57; .0001), MPL (1.50; .0003),
CCR1 (2.18; <.0001), CCL4L2
(1.72; <.0001), IL8 (1.84; <.0001),
CCR3 (−1.63; <.0001), TNFRSF1A
(1.69; .0005), IL1R2 (2.53;
<.0001), CCL3L3 (1.72; <.0001),
CXCL1 (2.63; <.0001),
TNFRSF12A (1.94; <.0001), CCL3
(2.0; <.0001), CXCR1 (1.67;
<.0001), CCL3L1 (2.0; <.0001),
PPBP (1.63; <.0001)
Chagas disease (1.54 × 10−9) C1QB (3.27; <.0001), JUN (1.84;
<.0001), C1QA (1.82; <.0001),
CCL2 (2.70; <.0001), GNA15
(1.82; <.0001), IL8 (1.84; <.0001),
C1QC (2.61; <.0001), TNFRSF1A
(1.69; .0005), CCL3L3 (1.72;
<.0001), CCL3 (2.0; <.0001), IL10
(−1.57; .0001), FOS (1.68;
<.0001), CCL3L1 (2.0; <.0001)
Complement and coagulation
cascade (3.67 × 10−9)
C1QB (3.27; <.0001), C1QA (1.82;
<.0001), PLAU (2.45; <.0001),
PLAUR (1.71; <.0001), C1QC
(2.61; <.0001), F13A1 (1.51;
.0001), C5AR1 (1.83; <.0001),
VWF (1.82; <.0001), PROS1 (1.57;
<.0001), THBD (2.83; <.0001),
C3AR1 (1.66; <.0001)
Rheumatoid arthritis
(4.85 × 10−9)
CTSL1 (1.85; .0002), JUN (1.84;
<.0001), CTLA4 (−1.77; .0004),
HLA-DQA1 (1.50; .0003), CCL2
(2.70; <.0001), IL8 (1.84; <.0001),
CCL3L3 (1.72; <.0001), CXCL1
(2.63; <.0001), CCL3 (2.0;
<.0001), FOS (1.68; <.0001), HLA-
DRB5 (−2.22; <.0001), CCL3L1
(2.0; <.0001)
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Components of the innate immune response were increased
in both RR and ENL, including C1q (C1QA, C1QB, and
C1QC). Interestingly, both RR and ENL had increased expres-
sion of hepcidin (HAMP) and cathelicidin (CAMP) antimicro-
bial peptides. Defensins were increased in ENL (DEFA1,
DEFA1B, DEFA3, and DEFA4) and in RR (DEFA4). Fc
receptor-like 3 and Fc receptor-like A were both decreased in
RR and ENL groups. IPA biomarkers analysis identiﬁed 12
Table 5 continued.
KEGG Pathway (Adjusted
P Value) Transcriptsa
Chemokine signaling pathway
(2.93 × 10−7)
CCL7 (3.40; <.0001), CCR1 (2.18;
<.0001), CCL4L2 (1.72; <.0001),
CCL2 (2.70; <.0001), GNG10
(1.59; .0005), CCR3 (−1.63;
<.0001), IL8 (1.84; <.0001),
CCL3L3 (1.72; <.0001), CXCL1
(2.63; <.0001), CCL3 (2.0;
<.0001), CXCL2 (2.81; <.0001),
CXCR1 (1.67; <.0001), CCL3L1
(2.0; <.0001), PPBP (1.63; <.0001)
Cell adhesion molecules
(4.15 × 10−7)
CD8A (−1.55; <.0001), ESAM (1.6;
<.0001), CTLA4 (−1.77; .0004),
HLA-DQA1 (1.50; .0003), PVRL2
(2.02; <.0001), SELP (1.62;
<.0001), SDC4 (1.88; .0001), CD6
(−1.68; .0001), CNTNAP2 (−1.78;
<.0001), HLA-C (1.85; <.0001),
HLA-DRB5 (−2.22; <.0001), JAM3
(1.55; <.0001)
Hematopoietic cell lineage
(8.40 × 10−7)
CD8A (−1.55; <.0001), CD24 (1.61;
<.0001), IL11RA (−1.61; <.0001),
FCGR1A (2.55; <.0001), ITGB3
(2.12; <.0001), IL1R2 (2.53;
<.0001), GP9 (1.53; <.0001), HLA-
DRB5 (−2.22; <.0001), ITGA2B
(2.36; <.0001), ANPEP (2.14;
<.0001)
Osteoclast differentiation
(2.99 × 10−6)
JUN (1.84; <.0001), CYLD (−1.56;
.0003), FCGR1A (2.55; <.0001),
PPARG (2.27; <.0001), ITGB3
(2.12; <.0001), FOSB (1.96;
<.0001), TNFRSF1A (1.69; .0005),
FOS (1.68; <.0001), FCGR3B
(1.61; .0002), FOSL1 (1.86;
<.0001), SOCS3 (1.89; <.0001)
Phagosome (1.86 × 10−5) CTSL1 (1.85; .0002), OLR1 (2.82;
<.0001), HLA-DQA1 (1.50; .0003),
FCGR1A (2.55; <.0001), ITGB3
(2.12; <.0001), HLA-C (1.85;
<.0001), FCGR3B (1.61; .0002),
ITGB5 (1.57; .0001), HLA-DRB5
(−2.22; <.0001), FCAR (1.68;
.0003), THBS1 (2.28; <.0001)
Asthma (2.43 × 10−5) FCER1A (−2.72; <.0001), IL10
(−1.57; .0001), RNASE3 (1.94;
<.0001), HLA-DQA1 (1.50; .0003),
HLA-DRB5 (−2.22; <.0001),
MS4A2 (−1.90; <.0001)
Malaria (3.72 × 10−5) IL10 (−1.57; .0001), SELP (1.62;
<.0001), CCL2 (2.70; <.0001),
GYPB (−2.45; <.0001), SDC4
(1.88; .0001), IL8 (1.84; <.0001),
THBS1 (2.28; <.0001)
ECM receptor interaction
(.0001)
GP9 (1.53; <.0001), VWF (1.82;
<.0001), ITGB5 (1.57; .0001),
SV2A (1.65; .0005), ITGA2B (2.36;
<.0001), SDC4 (1.88; .0001),
ITGB3 (2.12; <.0001), THBS1
(2.28; <.0001)
Leishmaniasis (.0004) JUN (1.84; <.0001), IL10 (−1.57;
.0001), FOS (1.68; <.0001), HLA-
DQA1 (1.50; .0003), FCGR3B
(1.61; .0002), FCGR1A (2.55;
<.0001), HLA-DRB5 (−2.22;
<.0001)
Table 5 continued.
KEGG Pathway (Adjusted
P Value) Transcriptsa
Toxoplasmosis (.003) PPIF (1.67; .0005), BIRC3 (−1.59;
.0002), HLA-DQA1 (1.50; .0003),
LDLR (1.89; <.0001), TNFRSF1A
(1.69; .0005), IL10 (−1.57; .0001),
HLA-DRB5 (−2.22; <.0001),
HSPA1B (1.68; .0001)
Amebiasis (.005) CXCL1 (2.63; <.0001), IL10 (−1.57;
.0001), ARG1 (2.10; <.0001),
GNA15 (1.82; <.0001), SERPINB2
(4.82; <.0001), IL8 (1.84; <.0001),
IL1R2 (2.53; <.0001)
T-cell receptor signaling
pathway (.006)
JUN (1.84; <.0001), CD8A (−1.55;
<.0001), IL10 (−1.57; .0001),
CTLA4 (−1.77; .0004), NFKBIE
(1.50; .0003), FOS (1.68; <.0001),
RASGRP1 (−1.64; .0003)
Antigen processing and
presentation (.006)
CTSL1 (1.85; .0002), CD8A (−1.55;
<.0001), HLA-C (1.85; <.0001),
HLA-DQA1 (1.50; .0003), HLA-
DRB5 (−2.22; <.0001), HSPA1B
(1.68; .0001)
Autoimmune thyroid disease
(.008)
IL10 (−1.57; .0001), CTLA4 (−1.77;
.0004), HLA-C (1.85; <.0001),
HLA-DQA1 (1.50; .0003), HLA-
DRB5 (−2.22; <.0001)
NOD-like receptor signaling
pathway (.02)
CXCL1 (2.63; <.0001), CXCL2 (2.81;
<.0001), BIRC3 (−1.59; .0002),
CCL2 (2.70; <.0001), IL8 (1.84;
<.0001)
Allograft rejection (.03) IL10 (−1.57; .0001), HLA-C (1.85;
<.0001), HLA-DQA1 (1.50; .0003),
HLA-DRB5 (−2.22; <.0001)
P53 signaling pathway (.04) ATM (−1.92; <.0001), SESN1
(−1.59; .0001), TP53I3 (1.67;
.0004), GADD45G (1.59; .0006),
THBS1 (2.28; <.0001)
Epithelial cell signaling in
Helicobacter pylori infection
(.04)
CXCL1 (2.63; <.0001), JUN (1.84;
<.0001), CXCR1 (1.67; <.0001),
JAM3 (1.56; <.0001), IL8 (1.84;
<.0001)
PPAR signaling pathway (.04) GK (2.0; <.0001), ACOX2 (2.10;
<.0001), ACSL1 (1.66; <.0001),
OLR1 (2.82; <.0001), PPARG
(2.27; .0003)
Abbreviations: ECM, extracellular matrix; ENL, erythema nodosum leprosum;
KEGG, Kyoto Encyclopedia of Genes and Genomes; NOD, nucleotide-binding
oligomerization domain; PPAR, peroxisome proliferator-activated receptor.
a Downregulated transcripts with negative fold changes are in italics.
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Table 6. Differentially Expressed Transcripts Unique to RR
Transcript Fold Changea P Value
IFI27 3.04 <.0001
HBQ1 2.65 <.0001
TGM2 2.63 <.0001
HBE1 2.58 <.0001
GBP1 2.45 <.0001
RBPMS2 2.43 <.0001
SLC25A37 2.31 <.0001
C2 2.31 <.0001
LOC647307 2.22 <.0001
LOC654055 2.20 <.0001
SERPING1 2.17 <.0001
OSBP2 2.16 <.0001
LOC649143 2.15 <.0001
IFIT3 2.10 <.0001
BATF2 2.08 <.0001
LOC653778 2.08 <.0001
TRIM58 2.07 <.0001
RAP1GAP 2.05 .0001
CXCL10 2.02 <.0001
LOC400759 1.99 <.0001
EPB49 1.95 <.0001
DPYSL5 1.92 <.0001
TACSTD2 1.91 <.0001
GMPR 1.91 <.0001
LOC654103 1.89 <.0001
TMOD1 1.89 <.0001
SLC6A10P 1.89 <.0001
E2F2 1.88 <.0001
IFITM3 1.87 <.0001
XK 1.85 <.0001
GPR175 1.85 <.0001
GBP5 1.84 <.0001
TRIM16L 1.83 <.0001
IL27 1.82 <.0001
FER1L3 1.81 .0001
PF4V1 1.81 <.0001
WARS 1.81 <.0001
OR2W3 1.80 <.0001
HLA-DRB6 1.79 <.0001
KCNJ2 1.78 <.0001
SDSL 1.78 <.0001
MARCO 1.77 <.0001
BLVRB 1.77 <.0001
MYOF 1.77 .0002
VAMP5 1.76 <.0001
HBEGF 1.76 <.0001
LOC642469 1.76 <.0001
LOC652616 1.73 .0001
LOC100133583 1.72 .0003
SERPINA13 1.71 <.0001
CLEC7A 1.71 .0002
Table 6 continued.
Transcript Fold Changea P Value
LOC642567 1.70 .0003
LOC729708 1.70 <.0001
HS.544245 1.69 .0001
IFIT2 1.67 .0001
SLC6A8 1.67 <.0001
TYMP 1.65 .0002
LOC100133678 1.65 .0001
SLC6A12 1.65 .0001
PANX2 1.64 .0002
ODF3B 1.63 .0003
MT2A 1.63 .0002
LOC100131391 1.62 .0001
CDCA5 1.62 .0002
ALDH1A1 1.61 .0001
BCL2L1 1.61 <.0001
LGALS3BP 1.61 .0001
PSG3 1.60 .0001
TK1 1.59 .0002
MME 1.59 .0003
BATF3 1.59 <.0001
LOC100133875 1.59 .0001
LOC650557 1.59 <.0001
MAFF 1.58 .0003
SAMD4A 1.56 .0003
PLA2G4C 1.56 .0002
CDC45L 1.56 .0003
LOC388588 1.54 <.0001
HSPA7 1.53 .0001
TUBB2A 1.52 .0002
VPREB3 −1.98 <.0001
TCL1A −1.98 <.0001
OSBPL10 −1.97 <.0001
SNORD4A −1.96 <.0001
ZNF256 −1.87 <.0001
ZNF101 −1.87 <.0001
ACACB −1.77 <.0001
CD19 −1.76 <.0001
SEL1L3 −1.74 <.0001
CCR7 −1.73 <.0001
FCGBP −1.71 <.0001
MGC3020 −1.71 <.0001
IRX3 −1.71 <.0001
LOC791120 −1.70 <.0001
FAIM3 −1.69 <.0001
EOMES −1.68 <.0001
LOC649841 −1.67 <.0001
FAM84B −1.67 .0001
SNORD104 −1.65 .0001
LEF1 −1.65 .0001
CXCR5 −1.65 <.0001
BLR1 −1.64 <.0001
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transcripts which could be potential biomarkers for RR or ENL,
including CCL2, CCL3, and SOD2. Transcripts increased in
PBMCs from both RR and ENL also included FcγR1 (CD64),
FPR1 and FPR2, and triggering receptor on myeloid cells 1
(TREM1) and the related molecule triggering receptor ex-
pressed on myeloid cells-like 1 (TREML1). FcγR1 recognizes
immunoglobulin G; FPR1 and FPR2 recognize formylated pep-
tides produced by bacteria and some mycobacteria [23].
Increased Monocyte-related Transcripts During RR and ENL
Changes in transcripts could reﬂect either a change in gene ex-
pression within PBMCs or a change in circulating cellular
Table 6 continued.
Transcript Fold Changea P Value
CD79A −1.64 <.0001
LOC283663 −1.63 <.0001
CACNA1I −1.63 <.0001
STRBP −1.62 .0002
SNHG7 −1.62 <.0001
MAL −1.61 <.0001
LOC651751 −1.61 <.0001
C21ORF2 −1.61 <.0001
CRYBB2 −1.60 .0001
LOC100132499 −1.60 <.0001
CD27 −1.60 <.0001
LRRN3 −1.60 <.0001
CMTM8 −1.60 <.0001
HLA-DRB1 −1.60 <.0001
KLHL3 −1.59 .0001
CYORF15A −1.59 <.0001
CDR2 −1.59 .0001
CD79B −1.59 <.0001
MC1R −1.57 .0001
LAMA5 −1.57 .0001
KLRF1 −1.57 .0001
LOC653316 −1.56 .0001
LOC90925 −1.56 <.0001
PLCH2 −1.55 .0001
KIAA0114 −1.55 <.0001
D4S234E −1.55 <.0001
CCDC102A −1.55 <.0001
HS.481464 −1.54 .0001
POU2AF1 −1.54 .0001
BLK −1.53 <.0001
C16ORF74 −1.53 <.0001
BEX2 −1.53 .0001
FCER2 −1.52 <.0001
HLA-DOB −1.50 .0001
CENTG2 −1.50 .0001
Abbreviation: RR, reversal reaction.
a Negative fold changes are in italic type.
Table 7. Differentially Expressed Transcripts Unique to ENL
Transcript Fold Changea P Value
OLFM4 3.09 <.0001
LTF 2.82 <.0001
OLR1 2.82 <.0001
CXCL2 2.81 <.0001
MMP8 2.46 <.0001
DEFA1B 2.44 <.0001
FAM20A 2.39 <.0001
LCN2 2.39 <.0001
SAMD14 2.33 <.0001
CEACAM8 2.30 <.0001
THBS1 2.28 <.0001
PPARG 2.27 <.0001
CEACAM6 2.26 <.0001
PHACTR1 2.25 <.0001
CHST13 2.21 <.0001
CCR1 2.18 <.0001
DEFA3 2.17 <.0001
ACOX2 2.10 <.0001
ARG1 2.09 <.0001
HTRA1 2.08 <.0001
C19ORF59 2.07 <.0001
PTPN20 2.06 <.0001
RNU11 2.06 <.0001
RGL1 2.05 <.0001
PHLDA1 2.03 <.0001
HS.562219 2.02 <.0001
PVRL2 2.02 <.0001
HIST2H2AC 2.01 <.0001
RNASE2 2.00 <.0001
CCRL2 1.99 <.0001
CEACAM1 1.98 <.0001
SLC22A18AS 1.98 <.0001
COL17A1 1.96 <.0001
TNFAIP6 1.96 <.0001
ZDHHC19 1.96 <.0001
SPRY2 1.95 <.0001
RNASE3 1.94 <.0001
BPI 1.93 <.0001
METTL7B 1.93 <.0001
C5ORF32 1.92 <.0001
DDIT3 1.92 <.0001
ELANE 1.92 <.0001
CYP1B1 1.89 <.0001
LDLR 1.89 <.0001
LOC649210 1.89 <.0001
PTAFR 1.89 .0001
RNASE1 1.89 <.0001
SOCS3 1.89 <.0001
PLP2 1.88 <.0001
TSPAN9 1.88 <.0001
CD300C 1.87 .0002
ASGR2 1.86 <.0001
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Table 7 continued.
Transcript Fold Changea P Value
GSN 1.86 <.0001
MAFB 1.86 <.0001
S100A12 1.86 <.0001
CETP 1.85 <.0001
HLA-C 1.85 <.0001
RNU4-1 1.85 <.0001
IL8 1.84 <.0001
JUN 1.84 <.0001
MGC29506 1.84 <.0001
SIGLEC9 1.84 .0002
AQP9 1.83 <.0001
C5AR1 1.83 <.0001
DOK3 1.83 .0001
LOC650263 1.83 <.0001
CEBPE 1.82 <.0001
GNA15 1.82 <.0001
LOC100133477 1.82 .0001
VWF 1.82 <.0001
DEFA1 1.81 <.0001
FBXL2 1.81 .0001
MIR1974 1.80 <.0001
RNU1-3 1.80 <.0001
RNU4-2 1.79 <.0001
SLC2A14 1.79 <.0001
C13ORF15 1.78 <.0001
LHFPL2 1.78 .0001
LOC100134331 1.78 <.0001
SERPINB8 1.78 .0001
ST14 1.78 <.0001
TMEM88 1.78 <.0001
HIST2H2BE 1.77 <.0001
BASP1 1.76 <.0001
FLVCR2 1.76 .0001
PPP1R15A 1.76 <.0001
TLE3 1.76 .0001
FAM129B 1.75 .0005
RGL4 1.75 <.0001
KIFC3 1.74 <.0001
LOC653061 1.74 <.0001
NAB2 1.74 <.0001
NRIP3 1.74 <.0001
ABCA1 1.73 <.0001
IGFBP2 1.73 <.0001
LOC441481 1.73 .0001
ABLIM3 1.72 <.0001
CCL3L3 1.72 <.0001
CCL4L2 1.72 <.0001
LOC728744 1.72 .0001
PLIN2 1.72 <.0001
CTDSPL 1.71 <.0001
MIR302C 1.71 .0004
Table 7 continued.
Transcript Fold Changea P Value
NOP10 1.71 .0005
PFKFB3 1.71 <.0001
HIST2H2AB 1.70 <.0001
SLC24A3 1.70 <.0001
STAB1 1.70 .0002
BEX1 1.69 .0001
HLX 1.69 <.0001
IRAK2 1.69 .0001
LIMK2 1.69 .0001
MIR223 1.69 .0001
RNU1-5 1.69 <.0001
SLC25A24 1.69 .0003
TNFRSF1A 1.69 .0005
FCAR 1.68 .0003
FOS 1.68 <.0001
HSPA1B 1.68 .0001
WIPI1 1.68 <.0001
ASPH 1.67 .0005
PPIF 1.67 .0005
RNU4ATAC 1.67 <.0001
SPHK1 1.67 .0004
TP53I3 1.67 .0004
ACSL1 1.66 <.0001
C3AR1 1.66 <.0001
ECM1 1.66 .0003
FAH 1.66 .0002
GAS6 1.66 .0001
HS.559602 1.66 .0002
IER3 1.66 <.0001
IGJ 1.66 <.0001
STEAP4 1.66 <.0001
CEACAM4 1.65 <.0001
H2AFJ 1.65 <.0001
LOC647506 1.65 <.0001
LOC650261 1.65 .0006
PSG9 1.65 <.0001
UBAP1 1.64 .0001
DCUN1D3 1.63 <.0001
LOC729040 1.63 .0004
PLSCR1 1.63 .0005
PPBP 1.63 <.0001
BST1 1.62 .0004
LOC728835 1.62 <.0001
RNU1G2 1.62 <.0001
SBNO2 1.62 .0004
SELP 1.62 <.0001
SGK1 1.62 <.0001
SLC2A5 1.62 <.0001
CD24 1.61 <.0001
DSE 1.61 <.0001
HIST1H1C 1.61 <.0001
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Table 7 continued.
Transcript Fold Changea P Value
LOC440731 1.61 .0003
ESAM 1.60 <.0001
PDLIM7 1.60 .0005
CD63 1.59 .0002
CDA 1.59 <.0001
GNG10 1.59 .0005
GPER 1.59 .0001
HIST1H3H 1.59 .0001
IGFBPL1 1.59 .0004
LOC100134728 1.59 <.0001
TRIB1 1.59 <.0001
AZU1 1.58 <.0001
H1F0 1.58 .0005
HS.521338 1.58 .0006
METRNL 1.58 <.0001
TNNT1 1.58 <.0001
ITGB5 1.57 .0001
RNU5A 1.57 .0001
UBTD1 1.57 .0005
40425 1.56 <.0001
JAM3 1.56 <.0001
SH3BGRL2 1.56 <.0001
SLC6A6 1.56 .0006
HIST2H3C 1.54 .0002
LOC100134379 1.54 <.0001
LOC649923 1.54 <.0001
NR1I2 1.54 .0005
TREML2 1.54 .0006
FLJ22662 1.53 .0002
GP9 1.53 <.0001
HOMER2 1.53 .0002
HS.557039 1.53 <.0001
IGLL1 1.53 <.0001
LOC554223 1.53 .0001
LOC647450 1.53 <.0001
NACC2 1.53 .0003
RAB13 1.53 .0001
SGK 1.53 <.0001
C5ORF62 1.52 .0003
HIST1H3F 1.52 .0001
HS.276854 1.52 .0002
LOC653506 1.52 .0001
ADORA2A 1.51 .0006
F13A1 1.51 .0001
LOC652493 1.50 <.0001
MPL 1.50 .0003
NFKBIE 1.50 .0003
FCER1A −2.72 <.0001
ERAP2 −2.48 <.0001
HDC −2.26 <.0001
HLA-DRB5 −2.22 <.0001
Table 7 continued.
Transcript Fold Changea P Value
NKTR −2.16 <.0001
MCOLN2 −2.05 <.0001
IFI44L −2.01 <.0001
OGT −1.98 <.0001
SAMD9L −1.95 <.0001
FAM46C −1.94 <.0001
HS.560343 −1.93 <.0001
ATM −1.92 <.0001
C7ORF54 −1.91 <.0001
PNN −1.91 <.0001
MS4A2 −1.90 <.0001
ZBTB20 −1.90 <.0001
HS.193767 −1.85 <.0001
C14ORF106 −1.84 <.0001
CD96 −1.84 <.0001
SFRS18 −1.84 <.0001
MTX3 −1.83 <.0001
TMEM181 −1.83 <.0001
HS.553301 −1.82 <.0001
C6ORF111 −1.81 <.0001
GVIN1 −1.80 <.0001
HS.22689 −1.80 <.0001
HS.556018 −1.80 <.0001
PHIP −1.80 <.0001
CCNJ −1.79 <.0001
TMX3 −1.79 <.0001
USPL1 −1.78 <.0001
CTLA4 −1.77 .0004
HS.356079 −1.77 <.0001
MYBL1 −1.77 <.0001
CEP350 −1.76 <.0001
FAM190B −1.76 <.0001
KIAA0528 −1.76 <.0001
LOC642333 −1.76 .0001
MGEA5 −1.76 <.0001
PTAR1 −1.76 <.0001
TTC3 −1.76 <.0001
ZNF518A −1.76 <.0001
C15ORF28 −1.75 <.0001
C6ORF190 −1.75 .0002
CROP −1.75 <.0001
TC2N −1.75 <.0001
C10ORF6 −1.74 <.0001
HS.481659 −1.74 <.0001
TTC14 −1.74 <.0001
TTC37 −1.74 <.0001
KNTC1 −1.73 .0002
ANKRD12 −1.72 <.0001
LOC100132247 −1.72 <.0001
ZFC3H1 −1.72 <.0001
DMTF1 −1.71 <.0001
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Table 7 continued.
Transcript Fold Changea P Value
HS.143018 −1.70 <.0001
MTM1 −1.70 .0002
PSME4 −1.70 .0002
RASGRP3 −1.70 <.0001
SAMD9 −1.70 <.0001
KIAA0907 −1.69 <.0001
PDS5A −1.69 .0004
CD6 −1.68 .0001
HEMGN −1.68 .0002
HS.202577 −1.68 <.0001
LOC729645 −1.68 <.0001
SAMD3 −1.68 .0003
ZNF33B −1.68 <.0001
EML4 −1.67 <.0001
HS.549989 −1.67 <.0001
HS.570988 −1.67 <.0001
LOC729978 −1.67 <.0001
OPTN −1.67 .0003
RBM33 −1.67 <.0001
ZNF512 −1.67 .0004
KIAA1128 −1.66 .0003
LOC613037 −1.66 .0001
RAX2 −1.66 .0003
SLC38A1 −1.66 .0004
CEP135 −1.65 .0002
HS.154336 −1.65 .0002
HS.535028 −1.65 <.0001
HS.571887 −1.65 .0004
PTGDR −1.65 <.0001
SLTM −1.65 .0002
STAT4 −1.65 .0001
TGFBR3 −1.65 .0001
LOC100134241 −1.64 <.0001
LOC23117 −1.64 <.0001
MIR142 −1.64 <.0001
RASGRP1 −1.64 .0003
TBC1D4 −1.64 .0001
CCDC66 −1.63 <.0001
CCR3 −1.63 <.0001
FLJ44342 −1.63 .0001
KIAA1641 −1.63 .0005
RBM25 −1.63 .0002
ZRANB2 −1.63 <.0001
ANAPC4 −1.62 .0004
CCDC14 −1.62 .0001
DKFZP586I1420 −1.62 <.0001
DPYSL4 −1.62 <.0001
FAM111A −1.62 .0004
HS.574671 −1.62 <.0001
MBNL1 −1.62 .0004
PFAAP5 −1.62 .0001
Table 7 continued.
Transcript Fold Changea P Value
SLC30A7 −1.62 .0002
YOD1 −1.62 .0002
CRIPAK −1.61 .0003
HS.374460 −1.61 <.0001
HS.445274 −1.61 .0001
HS.546375 −1.61 .0003
IL11RA −1.61 <.0001
ZNF721 −1.61 .0003
HS.193784 −1.60 .0002
HS.284464 −1.60 .0004
LCOR −1.60 .0004
LOC100131768 −1.60 .0001
ACAD11 −1.59 .0001
AHSA2 −1.59 <.0001
BIRC3 −1.59 .0002
HS.554324 −1.59 .0002
LOC729120 −1.59 .0002
SESN1 −1.59 .0001
ANGEL2 −1.58 .0001
C10ORF73 −1.58 .0004
HS.444683 −1.58 <.0001
KIAA1370 −1.58 .0003
PDK4 −1.58 <.0001
RASA4 −1.58 <.0001
VPS36 −1.58 .0001
C8ORF45 −1.57 <.0001
CCDC84 −1.57 <.0001
HS.473191 −1.57 .0002
IL10 −1.57 .0001
LOC728411 −1.57 .0002
MKLN1 −1.57 .0003
OLIG1 −1.57 <.0001
TARBP1 −1.57 .0005
ZNF529 −1.57 .0002
ZNF786 −1.57 .0002
CYLD −1.56 .0003
FAM153B −1.56 .0004
LOC441268 −1.56 <.0001
LRFN3 −1.56 .0001
ZNF224 −1.56 .0002
C10ORF137 −1.55 .0002
CD8A −1.55 <.0001
CTGLF3 −1.55 .0002
DMC1 −1.55 .0002
HS.440088 −1.55 .0004
HSD17B7 −1.55 .0005
D2HGDH −1.54 .0004
HS.371060 −1.54 .0002
KRT72 −1.54 <.0001
LYST −1.54 .0003
TXK −1.54 <.0001
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composition. To assess whether monocytosis was a potential
contributor to differential expression, we quantiﬁed the mono-
cyte population in PBMCs by gating and staining for CD14
(Supplementary Figure 1A) in patients with leprosy with RR
(n = 7), ENL (n = 8), or leprosy without reaction (n = 16).
Monocytes comprised 13.79%, 19.01%, or 15.77% of PBMCs
in RR, ENL, or no reaction, respectively (P = .45) (Supplemen-
tary Figure 1B). Furthermore, the majority of gated monocytes
were CD14+ in all groups (mean, 92.78%, 87.76%, or 92.28% in
RR, ENL, or no reaction, respectively; P = .54) (Supplementary
Figure 1C). Side scatter/forward scatter and CD14+ measures of
monocytes do not conﬁrm a signiﬁcant difference in the pro-
portion of circulating monocytes between reaction and nonre-
action PBMCs.
Conﬁrmation of Differential Gene Expression: Complement
Components
Given the current theory of augmented Th1 response to antigen
as the etiology of RR, ﬁndings of innate immune response as a
top GO pathway and complement and coagulation cascade as a
top KEGG pathway were interesting and suggestive of potential
overlap in immunologic response during RR and ENL. The
blue-pink o’gram representation of the array heat map for the
complement pathway components of the array is shown in
Supplementary Figure 2. Several components of the classic
Table 7 continued.
Transcript Fold Changea P Value
C2ORF69 −1.53 .0002
LOC202781 −1.53 .0002
RAB12 −1.53 <.0001
ZNF91 −1.53 .0001
FLJ12078 −1.52 <.0001
LOC100133950 −1.52 .0001
LOC440353 −1.52 .0005
LOC727908 −1.52 .0003
TBL1XR1 −1.52 .0004
BTAF1 −1.51 <.0001
C2ORF89 −1.51 .0005
CCDC45 −1.51 .0003
DTWD2 −1.51 .0003
LOC644297 −1.51 .0004
RPS23 −1.51 <.0001
SMCR5 −1.51 .0004
ZNF700 −1.51 .0002
INO80D −1.50 .0003
KIAA1333 −1.50 .0002
LOC645452 −1.50 .0002
PARP15 −1.50 .0005
Abbreviation: ENL, erythema nodosum leprosum.
a Negative fold changes are in italic type.
Table 8. Differentially Expressed Transcripts in Both RR and ENL
Groups
Transcript
RR ENL
Fold Changea P Value Fold Changea P Value
ADM 1.86 .0001 2.15 <.0001
ADORA2B 1.90 <.0001 2.09 <.0001
AHSP 2.74 <.0001 −2.52 <.0001
ALAS2 2.51 <.0001 −2.67 <.0001
ALPL 2.53 <.0001 3.65 <.0001
ANKRD22 3.15 <.0001 1.75 <.0001
ANPEP 1.82 <.0001 2.14 <.0001
ANXA3 1.97 <.0001 2.68 <.0001
AQP10 1.83 .0001 1.54 <.0001
AXIN2 −1.81 <.0001 −1.85 <.0001
BCL11B −1.58 .0002 −1.71 .0001
BPGM 1.53 .0002 −1.69 .0004
C15ORF48 2.60 <.0001 2.38 <.0001
C1QA 1.64 .0004 1.82 <.0001
C1QB 2.21 <.0001 3.27 <.0001
C1QC 1.77 <.0001 2.61 <.0001
C9ORF45 −1.76 <.0001 −1.63 <.0001
CA1 2.22 <.0001 −3.30 <.0001
CA4 2.26 <.0001 1.91 <.0001
CAMP 1.67 <.0001 2.16 <.0001
CCL2 2.90 <.0001 2.70 <.0001
CCL3 1.67 .0002 2.00 <.0001
CCL3L1 1.61 .0001 2.00 <.0001
CCL7 3.03 <.0001 3.40 <.0001
CEACAM3 1.74 <.0001 2.12 <.0001
CLEC5A 2.12 .0001 1.90 <.0001
CMTM2 1.73 <.0001 1.93 <.0001
CMTM5 1.59 .0001 1.97 <.0001
CNTNAP2 −2.03 <.0001 −1.78 <.0001
CTSL1 2.11 <.0001 1.85 .0002
CXCL1 1.64 .0001 2.63 <.0001
CXCR1 1.61 <.0001 1.67 <.0001
DEFA4 1.68 <.0001 2.60 <.0001
DHRS9 2.34 <.0001 1.83 .0002
DYSF 2.18 <.0001 1.86 <.0001
EDN1 1.62 .0001 1.71 .0003
EGR2 1.76 <.0001 1.58 <.0001
EMP1 1.92 .0002 1.82 <.0001
EPB42 2.20 <.0001 −2.85 <.0001
FCGR1A 2.78 <.0001 2.55 <.0001
FCGR1B 2.59 <.0001 2.38 <.0001
FCGR1C 2.87 <.0001 2.49 <.0001
FCGR3B 2.12 <.0001 1.61 .0002
FCRL3 −1.86 <.0001 −1.71 <.0001
FCRLA −2.32 <.0001 −1.65 <.0001
FFAR2 2.45 <.0001 2.02 <.0001
FOSB 1.68 .0001 1.96 <.0001
FOSL1 1.79 <.0001 1.86 <.0001
FPR1 1.80 .0001 2.10 <.0001
FPR2 2.28 <.0001 2.15 <.0001
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complement pathway had increased expression in PBMCs from
persons with RR or ENL (Table 9). C1qA, B, and C, comple-
ment component 2 (C2); and C1 esterase inhibitor (SERPING1)
were increased in RR. C1qA, B, and C and the complement re-
ceptors C3AR1 and C5AR1 were increased in ENL. Changes in
C1QB, C2, C1 esterase inhibitor, and C5AR1 expression in
PBMCs were validated with qPCR (Table 9).
The skin is a primary site of RR and ENL signs and symp-
toms, so we hypothesized that increased expression of C1q in
Table 8 continued.
Transcript
RR ENL
Fold Changea P Value Fold Changea P Value
G0S2 1.86 <.0001 1.60 <.0001
GADD45G 1.63 .0001 1.58 .0006
GAPDHL6 2.01 <.0001 1.51 <.0001
GK 2.05 <.0001 2.00 <.0001
GOLGA8B −1.52 <.0001 −2.13 <.0001
GPR109A 2.11 <.0001 2.93 <.0001
GPR109B 1.74 .0001 2.24 <.0001
GPR84 1.82 .0001 2.47 <.0001
GPR97 1.85 <.0001 1.90 <.0001
GYPB 2.25 <.0001 −2.45 <.0001
GYPE 1.62 .0001 −1.51 .0003
GZMK −1.83 <.0001 −1.52 <.0001
HAMP 1.74 .0003 1.89 .0004
HBD 2.53 <.0001 −2.48 <.0001
HBG1 1.76 <.0001 −2.14 <.0001
HBG2 1.67 <.0001 −2.06 <.0001
HBM 2.84 <.0001 −2.85 <.0001
HIST2H2AA3 1.77 <.0001 1.98 <.0001
HIST2H2AA4 1.72 <.0001 2.09 <.0001
HLA-A29.1 16.26 <.0001 −3.05 <.0001
HLA-DQA1 1.61 .0001 1.50 .0003
HP 1.58 .0001 2.55 <.0001
HS.572649 −1.71 <.0001 −1.62 <.0001
IFIT1L 1.92 <.0001 −3.03 <.0001
IL1R2 2.12 <.0001 2.53 <.0001
IL1RN 1.87 <.0001 1.97 <.0001
IL8RB 1.69 <.0001 1.51 .0004
ITGA2B 2.04 <.0001 2.36 <.0001
ITGB3 1.63 .0001 2.12 <.0001
KRT1 2.32 <.0001 −2.18 <.0001
LOC100131164 2.43 <.0001 −2.05 <.0001
LOC100133923 −1.55 <.0001 −1.90 <.0001
LOC100190986 −1.52 .0001 −2.01 <.0001
LOC389599 1.79 <.0001 −1.72 .0001
LOC440313 2.09 <.0001 −1.62 .0001
LOC642103 1.57 .0002 1.58 .0001
LOC643332 1.68 .0002 1.90 <.0001
LOC651309 −1.65 <.0001 −1.56 <.0001
LOC651524 2.04 <.0001 2.47 <.0001
LOC653600 1.61 <.0001 3.17 <.0001
LOC653610 2.12 <.0001 2.21 <.0001
LOC728499 −1.66 <.0001 −2.43 <.0001
LOC728715 1.55 .0002 1.71 .0001
LOC731682 1.93 <.0001 1.78 <.0001
LRG1 1.54 .0001 2.39 <.0001
LY6G6F 1.66 .0001 1.74 <.0001
MAP1A 1.59 .0002 1.83 <.0001
MIAT −1.60 <.0001 −2.30 <.0001
MMP9 2.39 <.0001 1.97 <.0001
MYL4 1.52 .0001 −1.74 <.0001
MYL9 2.14 <.0001 2.60 <.0001
Table 8 continued.
Transcript
RR ENL
Fold Changea P Value Fold Changea P Value
NAMPT 1.87 <.0001 1.68 <.0001
NFKBID 1.66 .0001 1.70 <.0001
NP 1.80 .0001 1.77 <.0001
ORM1 1.91 .0001 1.95 <.0001
PGLYRP1 1.92 <.0001 3.29 <.0001
PI3 2.30 <.0001 2.41 <.0001
PLAU 2.52 <.0001 2.45 <.0001
PLAUR 1.84 .0002 1.71 <.0001
PROK2 1.98 <.0001 1.98 <.0001
PROS1 1.50 .0003 1.57 <.0001
PVALB 1.91 <.0001 2.46 <.0001
RAB20 1.90 <.0001 1.93 <.0001
RETN 1.72 <.0001 2.97 <.0001
S100P 1.90 <.0001 2.59 <.0001
SDC4 1.58 .0002 1.88 .0001
SELENBP1 1.97 <.0001 −2.19 <.0001
SERPINB2 1.96 .0003 4.82 <.0001
SERTAD1 1.68 .0001 1.68 <.0001
SIGLEC16 1.58 .0003 1.64 .0002
SLC4A1 2.39 <.0001 −2.62 <.0001
SLPI 2.04 <.0001 3.72 <.0001
SNCA 2.06 <.0001 −1.54 .0003
SOD2 1.79 .0001 1.82 <.0001
STMN3 −1.63 <.0001 −1.51 .0003
STRADB 1.62 .0001 −1.92 <.0001
SV2A 1.68 .0001 1.65 .0005
TCN2 2.05 <.0001 1.86 <.0001
TGM3 1.92 <.0001 1.64 .0005
THBD 1.78 .0001 2.83 <.0001
TMEM158 1.57 .0001 2.63 <.0001
TNFRSF12A 1.94 <.0001 1.94 <.0001
TNNI2 1.53 .0001 1.72 .0002
TNS1 1.61 <.0001 −1.60 .0001
TP53INP2 1.70 .0001 1.76 <.0001
TREM1 1.78 .0002 1.88 <.0001
TREML1 1.64 .0001 2.40 <.0001
WDR40A 1.76 <.0001 −1.76 <.0001
Abbreviations: ENL, erythema nodosum leprosum; RR, reversal reaction.
a Negative fold changes are in italic type.
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PBMCs during RR or ENL could reﬂect increased deposition of
C1q in skin. Skin biopsy specimens from patients with leprosy
obtained as part of diagnostic workup for RR (n = 3), ENL
(n = 3), and borderline leprosy without reaction (n = 7 BT and
n = 3 BL/LL) were studied with immunohistochemistry. The
ﬂuorescent intensity of C1q staining was signiﬁcantly higher
in both RR and ENL compared with nonreaction leprosy
(P≤ .01) (Figure 2), indicating increased deposition of C1q in
reactional compared with nonreactional leprosy skin lesions.
DISCUSSION
Analysis of RR and ENL transcriptomes demonstrates distinct
pathways associated with the immune response. No validated
biomarker or effective prophylaxis is currently available for
RR and ENL [7, 8, 12, 24–26], and gene expression studies are
a crucial exploratory method to better understand reaction
pathogenesis. Some ﬁndings support previously published re-
sults on leprosy immunology. Of particular interest was the in-
creased expression of CXCL10 in the RR group, and its
identiﬁcation as a potential RR biomarker by IPA biomarkers
analysis, as CXCL10 has previously been proposed as a bio-
marker for RR [12]. The nucleotide-binding oligomerization
domain (NOD)-like receptor signaling pathway (KEGG) was
associated with ENL, an interesting ﬁnding given the associa-
tion of NOD2 with leprosy in a genome wide association
study [27]. IFN-γ was identiﬁed as an upstream regulator of dif-
ferential transcription in PBMCs of RR and ENL, which may be
a stimulus for immune cascade of reactions.
Pathway analysis showed a signiﬁcant involvement of the in-
nate immune system with RR and ENL. HAMP and CAMP
antimicrobial peptide transcripts were increased in RR and
ENL. CAMP expression is increased by a Toll-like receptor 1/
2–mediated process, and Toll-like receptor 2 polymorphisms
have been associated with increased risk of RR [28]. The com-
plement and coagulation pathway was an unexpected pathway
to ﬁnd enriched in the RR group, given the Th1 augmentation
theory of RR pathology, but our results support a potential role
in RR pathogenesis. We demonstrated increased deposition of
C1q in skin lesions of patients with leprosy with RR or ENL,
suggesting that complement is involved in both reaction types
systemically and in skin lesions. Interestingly, we did not ﬁnd
a signiﬁcantly different level of C1q deposition in tuberculoid
and lepromatous leprosy lesions, despite the different bacterial
burden and immune cell composition in the 2 leprosy poles.
That BT and BL/LL controls without immune reaction have
similar degree of C1q deposition in tissues supports association
of complement deposition with reactions rather than leprosy
per se. The increased complement deposition during reactions,
compared with baseline pathology due to leprosy, suggests that
complement deposition is part of the immune response in RR
and ENL.
The frequent association of reactions with recent initiation of
anti–M. leprae therapy parallels the pathologic immune activa-
tion that can occur when treatment is started for other infec-
tious diseases, such as human immunodeﬁciency virus and
Mycobacterium tuberculosis infection. Patients with tuberculo-
sis who go on to develop immune reconstitution inﬂammatory
Table 9. Selected Complement Components and Monocyte Receptor Transcript Expression in RR and ENL, as MeasuredWith Microarray
and qPCR Validation of a Subset of Transcripts
Complement Components and
Monocyte Receptors
RR ENL
Fold Increase in
Array (P Value)
Fold Increase in
qPCR (P Value)
Fold Increase in
Array (P Value)
Fold Increase in
qPCR (P Value)
Complement pathway component
C1Q (subunit A) 1.64 (.0004) NA 1.82 (<.0001) NA
C1Q (subunit B) 2.21 (<.0001) 1.72 (.005) 3.27 (<.0001) 2.63 (.07)
C1Q (subunit C) 1.77 (<.0001) NA 2.61 (<.0001) 3.45 (.03)
C2 2.31 (<.0001) 1.94 (.01) Not significant NA
C1 esterase inhibitor 2.17 (<.0001) 2.18 (.001) Not significant NA
C5AR1 Not significant NA 1.83 (<.0001) 1.60 (.005)
Monocyte receptor
FcγRI (CD64) 2.78 (<.0001) 2.22 (.0002) 2.55 (<.0001) 2.39 (.005)
FPR-1 1.80 (.0001) 1.81 (.0002) 2.10 (<.0001) 1.84 (.006)
FPR-2 2.3 (<.0001) 2.05 (<.0001) 2.15 (<.0001) 1.87 (.01)
MARCO 1.77 (<.0001) 1.91 (.001) Not significant NA
CLEC7A or dectin-1 1.71 (.0002) 1.67 (.004) Not significant NA
Abbreviations: CLEC7A, C-type lectin domain family 7, member A; ENL, erythema nodosum leprosum; FcγRI, Fc fragment of IgG receptor-1; FPR, percentage false-
positive; MARCO, macrophage receptor with collagenous structure; NA, not available; qPCR, quantitative polymerase chain reaction; RR, reversal reaction.
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syndrome (IRIS) have increased C1q expression at initiation
and after 2 weeks of antiretroviral treatment [29, 30]. Patients
with tuberculosis and IRIS have increased C1 inhibitor at base-
line without further increase in C1 inhibitor 2 weeks after start-
ing antiretroviral therapy, as was seen in controls. Tran et al [30]
hypothesized that mycobacterial antigen load may drive the
complement activation they observed during tuberculosis with
IRIS. PBMCs from patients with leprosy with a history of RR
have, in response to stimulation with M. leprae antigen, an in-
creased expression of genes associated with monocyte recruitment
and the innate immune response [8]. “Antigen processing and
presentation” KEGG pathways were associated with RR and
ENL in this microarray analysis, which supports contribution
of antigen to RR and ENL pathogenesis. HLA associations
have been made with leprosy [31, 32], although the contribution
of HLA expression to antigen presentation and immune re-
sponse during RR and ENL needs to be described. Our ﬁndings
of transcriptional differences of HLA genes could inform future
studies of HLA types and risk of immune reactions.
A major strength of this study is the description of PBMC
gene expression from persons with active, untreated immune
reactions compared with controls matched for age, sex, and
clinical form of leprosy. Matching for stage of leprosy treatment
in the array was a control for effects of antileprosy therapy and
stage of leprosy disease on gene expression. Furthermore,
samples were collected and processed before initiation of immu-
nomodulatory therapies. We were also able to investigate corre-
lation of gene expression differences of C1q in PBMCs to
presence in skin during reactions. We minimized potential
type 2 errors associated with large-scale array comparisons by
Figure 2. Intensity of ﬂuorescent staining for C1q (A) with representative photographs (B) in skin lesions of reversal reaction (RR; n = 3), erythema no-
dosum leprosum (ENL; n = 3), borderline tuberculoid (BT) controls (n = 7), and borderline lepromatous (BL)/ lepromatous leprosy (LL) (n = 3) controls. Differ-
ences in groups were determined with analysis of variance and Tukey multiple-comparison test. *P≤ .05; †P≤ .01; ‡P≤ .001. Error bars denote standard
error of the mean.
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applying stringent criteria (FPR, ≤0.05; P ≤ .05; fold change
≥1.5 or ≤−1.5) for transcripts used for functional and biologic
pathway analyses. Study limitations include analysis of gene ex-
pression in PBMCs rather than whole blood, because conclu-
sions are relevant for the isolated monocyte and lymphocyte
populations. The PBMC and biopsy specimens used were not
from the same patients, which needs to be considered when as-
sessing experimental conclusions.
We hypothesize that both RR and ENL may have disordered
recognition responses to M. leprae antigen with increased pro-
duction of antibodies or heightened responsiveness to antibodies,
with pathology mediated by complement and other components
of innate immunity. Differences in the clinical presentation of RR
and ENL may be related to several factors, including M. leprae
burden and the balance between humoral and cell-mediated im-
mune responses to M. leprae and other antigens. Genetic factors
have also been proposed as risk factors for immune reactions
[28]. Further investigations of the involvement of innate immu-
nity, including complement and antimicrobial peptides, and
IFN-γ–mediated processes are indicated to fully elucidate the
pathophysiology of leprosy immune reactions.
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